Kotani Ai, Okazaki Il-Mi, Muramatsu Masamichi, Kinoshita Kazuo, Begum Nasim A, Nakajima Toshiharu, Saito Hirohisa, Honjo Tasuku
Department of Medical Chemistry and Molecular Biology, Graduate School of Medicine, Kyoto University, Yoshida Konoe-Cho, Sakyo-Ku, Kyoto 606-8501, Japan.
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4506-11. doi: 10.1073/pnas.0500830102. Epub 2005 Mar 14.
Activation-induced cytidine deaminase (AID) is essential for somatic hypermutations (SHM) and class switch recombination. Overexpression of AID in non-B cells can induce SHM in artificial constructs inserted in various loci in the genome. AID overexpression was thus proposed to introduce mutations in a wide variety of genes with little specificity. We previously showed that AID transgenic mice developed T cell lymphomas in which the variable region beta genes of the T cell receptor and c-myc were mutated as frequently as SHM in activated B cells. To understand the target specificity of SHM in AID-expressing T lymphomas, we sequenced six oncogenes (c-myc, pim1, p53, atm, tgfbr-2, and k-ras) and two genes (cd4 and cd5) that are actively transcribed in T lymphomas. SHM was found only in c-myc, pim1, cd4, and cd5, which share the E47 binding motif in the enhancer/promoter. The rest that are not mutated in B cells were not mutated in AID-induced T lymphomas either, although they are transcribed in T and B cells. Comparison of several features of SHM, including selection of targets and mutation distribution, suggests that the regulatory mechanism of SHM is similar between T and B cells. SHM base specificities in the CD4 and CD5 genes were biased to AT, indicating that the preference of target bases of the mutations generated by overexpression of AID is not always GC bases but variable between target genes.
激活诱导的胞苷脱氨酶(AID)对于体细胞超突变(SHM)和类别转换重组至关重要。在非B细胞中过表达AID可在插入基因组各个位点的人工构建体中诱导SHM。因此,有人提出AID过表达会在多种基因中引入突变,且特异性较低。我们之前表明,AID转基因小鼠会发生T细胞淋巴瘤,其中T细胞受体的可变区β基因和c-myc的突变频率与活化B细胞中的SHM一样高。为了了解表达AID的T淋巴瘤中SHM的靶标特异性,我们对六个癌基因(c-myc、pim1、p53、atm、tgfbr-2和k-ras)以及在T淋巴瘤中活跃转录的两个基因(cd4和cd5)进行了测序。仅在c-myc、pim1、cd4和cd5中发现了SHM,它们在增强子/启动子中共享E47结合基序。其余在B细胞中未发生突变的基因,在AID诱导的T淋巴瘤中也未发生突变,尽管它们在T细胞和B细胞中均有转录。对SHM的几个特征(包括靶标选择和突变分布)的比较表明,T细胞和B细胞之间SHM的调控机制相似。CD4和CD5基因中的SHM碱基特异性偏向于AT,这表明AID过表达产生的突变的靶标碱基偏好并不总是GC碱基,而是在不同靶标基因之间存在差异。